Welcome to our dedicated page for Portage Biotech SEC filings (Ticker: PRTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a clinical-stage biotech filing often means decoding scientific jargon, tracing trial milestones, and calculating how many quarters of cash runway remain. Portage Biotech’s disclosures are no exception—Form 10-K footnotes detail immuno-oncology pipelines while 8-K updates announce pivotal study data. If you have ever wondered, “Where do I track Portage Biotech insider trading Form 4 transactions in real time?” or “How can I quickly review the latest Portage Biotech quarterly earnings report 10-Q filing?,” you are in the right place.
Stock Titan’s AI engine continually scans EDGAR and delivers plain-English summaries the moment a document drops. Complex R&D tables become one-sentence insights, and risk-factor sections are distilled into key bullets. You will find:
- 10-K & 10-Q reports—cash burn, pipeline progress, and segment spending, all highlighted by AI for easy comparison.
- Form 4 alerts—Portage Biotech Form 4 insider transactions real-time, including executive stock transactions before clinical read-outs.
- 8-K disclosures—material events such as trial results or licensing deals, with Portage Biotech 8-K material events explained in clear language.
- DEF 14A proxy filings—Portage Biotech proxy statement executive compensation trends simplified.
Whether you need a Portage Biotech annual report 10-K simplified, an at-a-glance Portage Biotech earnings report filing analysis, or help understanding Portage Biotech SEC documents with AI, our platform keeps every filing searchable, summarized, and context-ready. Spend less time scrolling and more time acting on the immuno-oncology insights that drive value.
Portage Biotech has entered into an At The Market (ATM) Offering Agreement with Rodman & Renshaw LLC on June 27, 2025. Through this agreement, Portage can offer and sell ordinary shares with an aggregate offering price of up to $3,377,250.
Key details of the ATM offering:
- Sales will be conducted through various methods including privately negotiated transactions, block transactions, and "at the market offerings" on Nasdaq Capital Market
- Rodman will receive a 3.0% commission on gross sales
- The offering will terminate upon reaching the full amount or early termination of the agreement
- Sales will be made under the shelf registration Form F-3 (File No. 333-286961) declared effective May 14, 2025
This strategic move provides Portage with flexibility in raising capital through controlled equity distributions. The filing includes legal opinions and necessary exhibits confirming the arrangement's compliance with securities regulations.
Portage Biotech has filed a prospectus supplement for an "at the market" offering of ordinary shares worth up to $3,377,250 through Rodman & Renshaw LLC as sales agent. The shares will be sold on the Nasdaq Capital Market (PRTG) where the last reported price was $5.96 per share on June 26, 2025.
Key offering details:
- Sales agent commission: Up to 3.0% of gross sales price
- Public float: Approximately $10,131,750 (855,000 shares at $11.85)
- Offering limitations: Cannot exceed one-third of public float ($3,377,250) in any 12-month period due to Form F-3 restrictions
The company, a clinical-stage immune-oncology firm developing first-in-class cancer therapies, recently faced operational challenges. In January 2024, they discontinued their iNKT program trial due to funding issues, and in April 2024 paused patient accrual for their adenosine trial program. This offering appears aimed at raising additional capital to support ongoing operations.
Portage Biotech (NASDAQ: PRTG) has filed a prospectus supplement related to 481,581 Ordinary Shares underlying Warrants. The key development is the company's regaining of compliance with Nasdaq's continued listing requirements, specifically the minimum stockholders' equity requirement for The Nasdaq Capital Market.
Key points from the filing:
- The company's stock closed at $5.60 on June 24, 2025 on Nasdaq
- The filing updates the original prospectus dated November 7, 2023, which is part of Form F-1 Registration No. 333-275229
- This supplement incorporates information from Form 6-K filed on June 25, 2025
- The company is a clinical-stage immuno-oncology firm developing novel biologics for cancer treatment
The filing includes standard risk disclaimers and forward-looking statements regarding financing, going concern status, and scientific results. The document is signed by CFO Andrea Park and includes incorporation by reference into Forms S-8 and F-3 registration statements.
Portage Biotech has successfully regained compliance with Nasdaq Capital Market's minimum stockholders' equity requirement, as announced in a Form 6-K filed on June 28, 2025. The company received official notice from Nasdaq on June 24, 2025, confirming their compliance status and closing the previously announced listing matter.
Key points from the filing:
- Filing incorporates by reference into Form S-8 (File No. 333-275842) and Form F-3 (File No. 333-286961) registration statements
- Company maintains its listing on the Nasdaq Capital Market
- Press release dated June 25, 2025, included as Exhibit 99.1
- Document signed by CFO Andrea Park
This development is significant for investors as it confirms Portage Biotech's continued compliance with Nasdaq listing requirements, ensuring maintained access to public markets and investor visibility.
FAQ
What is the current stock price of Portage Biotech (PRTG)?
What is the market cap of Portage Biotech (PRTG)?
What is the core focus of Portage Biotech Inc?
How does Portage Biotech generate its revenue?
What makes Portage Biotech unique in the biotech industry?
Which areas of pharmaceutical research does Portage Biotech engage in?
What does the company’s pipeline consist of?
How is Portage Biotech managing its operational expenses?
How does Portage Biotech position itself within the competitive biotech sector?
What kind of research methodologies does Portage Biotech utilize?
